The Department of Health and Human Services will begin restoring a payment rate of average sales price plus 6% for 340B drug claims in about two weeks, the department told a United States District Court for the District of Columbia.  
  
In a brief filed late Friday evening, HHS wrote that “the process of adjusting the 2022 OPPS payment rates for 340B hospitals would take approximately two weeks” because it “requires revisions to four different electronic data files and then testing by multiple offices to confirm that the revised files function appropriately before the files are loaded to the production environment where they will be used to calculate OPPS reimbursements on a prospective basis.” HHS has already started work on this process, and 340B hospitals should expect to see the reimbursement adjustments within this timeframe. 
  
Last week, the district court ruled in favor of the AHA, holding that HHS must immediately halt the departments’ unlawful cuts of nearly 30% to outpatient reimbursement rates for the remainder of 2022 for certain hospitals that participate in the 340B Drug Pricing Program. 
  
In a statement last week, AHA General Counsel and Secretary Melinda Hatton said that “halting these cuts will help 340B hospitals provide comprehensive health services to their patients and communities.”  
  
Earlier this year, the U.S. Supreme Court declared HHS’ 340B cuts for 2018 and 2019 were unlawful, but had not ruled on 2020 or afterward. The AHA continues to urge the Administration to promptly reimburse all the hospitals that were affected by these unlawful cuts in previous years and to ensure the remainder of the hospital field is not penalized for the departments’ prior unlawful policy.

Related News Articles

Headline
The Department of Health and Human Services April 18 finalized its rule to establish a 340B Administrative Dispute Resolution process as required under the…
Headline
Sen. John Thune, R-S.D., April 16 updated AHA members on progress to extend telehealth waivers, offering hope that a solution will arise in end-of-year…
Headline
AHA March 26 submitted comments on a discussion draft of the SUSTAIN 340B Act, legislation proposed in the Senate to clarify Congress’ intent in creating the…
Headline
AHA March 12 released a new report from Healthsperien on discounts to 340B hospitals through the 340B Drug Pricing Program relative to drug company revenues…
Headline
The U.S. Court of Appeals for the 8th Circuit March 12 upheld Arkansas’ 340B Drug Pricing Nondiscrimination Act against a constitutional challenge brought by…
Headline
AHA Feb. 29 filed a friend-of-the-court brief in support of a Louisiana law that prohibits drug companies from denying Louisiana hospitals the same 340B…